At the beginning of this century, the Amaryllidaceae alkaloid galanthamine was approved by the Food and Drug Administration (FDA) for the clinical treatment of AD because of its acetylcholinesterase inhibitory activity [14]. Here, ACHE is linked to Alzheimer disease.